Drugs / AVX70371
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06989788 | May 2025 → Aug 2026 overdue | chronic hepatitis B virus infection | AstriVax Therapeutics | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-05 | AstriVax Therapeutics | AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology astrivax.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX70371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06989788 ↗ |
| Modality | Vaccine | “Investigational Therapeutic Hepatitis B Virus (HBV) Vaccine” NCT06989788 ↗ |